Canagliflozin Inhibits Human Endothelial Cell Inflammation Through the Induction of Heme Oxygenase-1

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Aug 12

PMID 35955910

Authors

Kelly J Peyton

Ghazaleh Behnammanesh

Giovanna L Durante

William Durante

Affiliations

Soon will be listed here.

Abstract

Sodium-glucose co-transporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in patients with type 2 diabetes mellitus (T2DM). Studies have also shown that canagliflozin directly acts on endothelial cells (ECs). Since heme oxygenase-1 (HO-1) is an established modulator of EC function, we investigated if canagliflozin regulates the endothelial expression of HO-1, and if this enzyme influences the biological actions of canagliflozin in these cells. Treatment of human ECs with canagliflozin stimulated a concentration- and time-dependent increase in HO-1 that was associated with a significant increase in HO activity. Canagliflozin also evoked a concentration-dependent blockade of EC proliferation, DNA synthesis, and migration that was unaffected by inhibition of HO-1 activity and/or expression. Exposure of ECs to a diabetic environment increased the adhesion of monocytes to ECs, and this was attenuated by canagliflozin. Knockdown of HO-1 reduced the anti-inflammatory effect of canagliflozin which was restored by bilirubin but not carbon monoxide. In conclusion, this study identified canagliflozin as a novel inducer of HO-1 in human ECs. It also found that HO-1-derived bilirubin contributed to the anti-inflammatory action of canagliflozin, but not the anti-proliferative and antimigratory effects of the drug. The ability of canagliflozin to regulate HO-1 expression and EC function may contribute to the clinical profile of the drug.

Citing Articles

SGLT2 inhibitors for alleviating heart failure through non-hypoglycemic mechanisms.

Chen Y, Zhu F, Zhou R Front Cardiovasc Med. 2024; 11:1494882.

PMID: 39717441 PMC: 11663900. DOI: 10.3389/fcvm.2024.1494882.

The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation.

Ridha-Salman H, Al-Zubaidy A, Abbas A, Hassan D, Malik S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39254877 DOI: 10.1007/s00210-024-03406-y.

Applications of SGLT2 inhibitors beyond glycaemic control.

OHara D, Lam C, McMurray J, Yi T, Hocking S, Dawson J Nat Rev Nephrol. 2024; 20(8):513-529.

PMID: 38671190 DOI: 10.1038/s41581-024-00836-y.

Emerging role of antidiabetic drugs in cardiorenal protection.

Fu W, Huo J, Mao Z, Pan S, Liu D, Liu Z Front Pharmacol. 2024; 15:1349069.

PMID: 38384297 PMC: 10880452. DOI: 10.3389/fphar.2024.1349069.

SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis.

Zhang Q, Deng Z, Li T, Chen K, Zeng Z Front Cardiovasc Med. 2024; 10:1280547.

PMID: 38274313 PMC: 10808651. DOI: 10.3389/fcvm.2023.1280547.

References

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Behnammanesh G, Durante G, Khanna Y, Peyton K, Durante W . Canagliflozin inhibits vascular smooth muscle cell proliferation and migration: Role of heme oxygenase-1. Redox Biol. 2020; 32:101527. PMC: 7152682. DOI: 10.1016/j.redox.2020.101527. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Beckman J, Creager M, Libby P . Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA. 2002; 287(19):2570-81. DOI: 10.1001/jama.287.19.2570. View

Devineni D, Polidori D . Clinical Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Profile of Canagliflozin, a Sodium-Glucose Co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015; 54(10):1027-41. DOI: 10.1007/s40262-015-0285-z. View

Uthman L, Kuschma M, Romer G, Boomsma M, Kessler J, Hermanides J . Novel Anti-inflammatory Effects of Canagliflozin Involving Hexokinase II in Lipopolysaccharide-Stimulated Human Coronary Artery Endothelial Cells. Cardiovasc Drugs Ther. 2020; 35(6):1083-1094. PMC: 8578058. DOI: 10.1007/s10557-020-07083-w. View

Cefalu W, Leiter L, Yoon K, Arias P, Niskanen L, Xie J . Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382(9896):941-50. DOI: 10.1016/S0140-6736(13)60683-2. View

Mancini S, Boyd D, Katwan O, Strembitska A, Almabrouk T, Kennedy S . Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018; 8(1):5276. PMC: 5869674. DOI: 10.1038/s41598-018-23420-4. View

Brownlee M . The pathobiology of diabetic complications: a unifying mechanism. Diabetes. 2005; 54(6):1615-25. DOI: 10.2337/diabetes.54.6.1615. View

10.

Kawamura K, Ishikawa K, Wada Y, Kimura S, Matsumoto H, Kohro T . Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2004; 25(1):155-60. DOI: 10.1161/01.ATV.0000148405.18071.6a. View

11.

McClung J, Levy L, Garcia V, Stec D, Peterson S, Abraham N . Heme-oxygenase and lipid mediators in obesity and associated cardiometabolic diseases: Therapeutic implications. Pharmacol Ther. 2021; 231:107975. PMC: 8958338. DOI: 10.1016/j.pharmthera.2021.107975. View

12.

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

13.

Hinds Jr T, Stec D . Bilirubin, a Cardiometabolic Signaling Molecule. Hypertension. 2018; 72(4):788-795. PMC: 6205727. DOI: 10.1161/HYPERTENSIONAHA.118.11130. View

14.

Matheus A, Tannus L, Cobas R, Palma C, Negrato C, Gomes M . Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013; 2013:653789. PMC: 3603160. DOI: 10.1155/2013/653789. View

15.

Niu Y, Zhang Y, Zhang W, Lu J, Chen Y, Hao W . Canagliflozin Ameliorates NLRP3 Inflammasome-Mediated Inflammation Through Inhibiting NF-κB Signaling and Upregulating Bif-1. Front Pharmacol. 2022; 13:820541. PMC: 8996145. DOI: 10.3389/fphar.2022.820541. View

16.

Zelniker T, Wiviott S, Raz I, Im K, Goodrich E, Bonaca M . SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018; 393(10166):31-39. DOI: 10.1016/S0140-6736(18)32590-X. View

17.

Liu X, Peyton K, Durante W . Ammonia promotes endothelial cell survival via the heme oxygenase-1-mediated release of carbon monoxide. Free Radic Biol Med. 2016; 102:37-46. PMC: 5209302. DOI: 10.1016/j.freeradbiomed.2016.11.029. View

18.

Hasan R, Lasker S, Hasan A, Zerin F, Zamila M, Chowdhury F . Canagliflozin attenuates isoprenaline-induced cardiac oxidative stress by stimulating multiple antioxidant and anti-inflammatory signaling pathways. Sci Rep. 2020; 10(1):14459. PMC: 7468124. DOI: 10.1038/s41598-020-71449-1. View

19.

Kosiborod M, Cavender M, Fu A, Wilding J, Khunti K, Holl R . Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose.... Circulation. 2017; 136(3):249-259. PMC: 5515629. DOI: 10.1161/CIRCULATIONAHA.117.029190. View

20.

Peyton K, Reyna S, Chapman G, Ensenat D, Liu X, Wang H . Heme oxygenase-1-derived carbon monoxide is an autocrine inhibitor of vascular smooth muscle cell growth. Blood. 2002; 99(12):4443-8. DOI: 10.1182/blood.v99.12.4443. View